UCB uses Byteflies wearables to monitor seizures
August 29, 2017
Belgian biopharmaceutical company UCB (Union Chimique Belge) is to use wearable technology from local start-up Byteflies to monitor difficult-to-measure seizures experienced by people with epilepsy.
This collaboration with UCB is an important step forward for Byteflies, and builds on a recent successful funding round from a group of American and Belgian investors that raised $600,000.
"We are very pleased with this funding, which will not only give us the necessary resources to grow, but also provides us with the expertise of our investors to lead our company towards the next step," said Hans Danneels, CEO and co-founder of Byteflies.
Byteflies wants to become the reference in wearable health products. With a toolkit of specialised wearables, and an accompanying data platform, the company is targeting the pharmaceutical industry, start-ups and research groups.
Before the end of this year, Byteflies plans to launch a wearable health toolkit to accelerate clinical trials and research.
The wearables are being used in a monitoring project for UCB. As part of a consortium, which includes UCB, the University of Leuven, the Leuven University Hospital and product developer PiliPili, Byteflies is providing discreet and accurate monitoring of difficult-to-measure seizures in a test group of patients.
“In partnership with Byteflies, UCB is excited to be at the forefront of next generation wearables, collaborating to evaluate the benefits of measuring patient symptoms and experiences which, in the future, could support individually tailored care approaches,” said Erik Janssen, vice president of UCB. “Everything we do at UCB is inspired by patients, and driven by science. In this regard, harnessing technology and innovation are crucial elements in our mission to provide maximum value to those patients who need it the most.”
Headquartered in Belgium, Byteflies has a second office, in Silicon Valley.